62results about How to "Solubility" patented technology

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

A method for producing a nitride crystal, comprising growing a nitride crystal on the surface of a seed crystal put in a reactor while the temperature and the pressure inside the reactor that contains, as put thereinto, a seed crystal having a hexagonal-system crystal structure, a nitrogen-containing solvent, a starting material, and a mineralizing agent containing fluorine and at least one halogen element selected from chlorine, bromine and iodine are so controlled that the solvent therein could be in a supercritical state and / or a subcritical state to thereby grow a nitride crystal on the surface of the seed crystal in the reactor.

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

A vehicle for topical delivery which contains a liquid eutectic mixture of hydrophobic compounds.

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Various methodologies for the immobilization of molecules such, as multistranded nucleic acid molecules, are described. The methodologies include activation of solid supports, as well as treatment of, e.g. termini of nucleic acid molecules to render them more receptive to immobilization on surfaces.

The invention relates to pharmacology and may be used for producing medicinal agents for treating and preventing viral diseases caused by the herpes, influenza and hepatitis B and C viruses, and also virus-induced immunodeficiencies. A biologically active substance having a polypharmacological effect is made from the green parts and spikelets of cereals of the family Gramineae, genus Calamagrostis Adans and / or genus Deschampsia Beauv, and contains flavonoids, specifically aglycones of the flavonoids tricin, apigenin, luteolin, quercetin and rhamnazin, and / or flavonoid glycosides of tricin, apigenin, luteolin, quercetin, and rhamnazin, and excipients, and has the following composition by mass percent: tricin flavonoid aglycone and / or tricin flavonoid glycosides: 0.016-2.062%; apigenin flavonoid aglycone and / or apigenin flavonoid glycosides: 0.010-1.393%; luteolin flavonoid aglycone and / or luteolin flavonoid glycosides: 0.01-4.979%; quercetin flavonoid aglycone and / or quercetin flavonoid glycosides: 0.001-0.771%; rhamnazin flavonoid aglycone and / or rhamnazin flavonoid glycosides: 0.104-0.203%; excipients: 99.868-90.592%. In this way, the biologically active substance is perfected by determining the specific compositions of the active ingredients thereof, and the physical, chemical and biological characteristics thereof, resulting in the invention of an optimal composition (FIG. 1) for achieving an antiviral effect with regard to specific viruses, and dosages when creating medicinal forms. In addition, it has been determined that the biologically active substance is an inducer of a type-γ endogenous interferon, displays an apoptosis-modulating effect, has antioxidant properties and enhances cell resistance to free radical stress. The antiviral effect with regard to specific viruses has been established to be an antiviral effect with regard to the type 2 herpes simplex virus, the influenza virus, and the bovine viral diarrhea virus (hepatitis C virus).

The invention relates to varenicline hemitartrate and a preparing method thereof. The salt has a structure shown as the formula II. The varenicline hemitartrate is good in stability, low in moisture adsorption and high in safety. The preparing method is simple in operation and good in reproducibility.

The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(−) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).

The invention discloses peony seed oil cleansing oil and a preparation method thereof. The peony seed oil cleansing oil is prepared from the following components in percentage by mass: 42-50% of peonyseed oil, 30-40% of olive oil, 8-10% of ethylhexyl palmitate, 8-10% of PEG-20 glyceryl triisostearate, and 1-1.5% of tocopheryl acetate. By deploying the type and content of vegetable oil, the problems that when the peony seed oil is independently used, the cost is high, and when the olive oil is independently used, burden is prone to being generated on the skin are solved; and through optimization of an emulsifier and other assistants, the prepared cleansing oil has the high dissolving capacity on cosmetics, when fresh water is added for massage and emulsification after cleansing, the particle size of an emulsion is small, flushing is easy, no oil film is left on the skin after flushing, pores can be deeply cleaned without excessive cleaning, and the skin is not tight after washing.

The present invention relates to ready to dilute injectable formulations of bortezomib comprising bortezomib, non-aqueous solvents enhancing the solubility and pH modifying agent.